- Home
- IBG vs VBIO Comparison
IBG vs VBIO Comparison
Compare IBG & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBG | VBIO |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IBG | VBIO |
|---|---|---|
| Price | $0.97 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.4K | ★ 17.6M |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $0.11 |
| 52 Week High | $6.50 | $1.30 |
Technical Indicators
Market Signals| Indicator | IBG | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 24.00 |
| Support Level | $0.71 | N/A |
| Resistance Level | $0.93 | $0.44 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 34.98 | 0.78 |
Price Performance
Historical ComparisonAbout IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.